Revenue Grows by 115% and the Company Records Positive Adjusted EBITDA for the Second Quarter of 2019 Conference Call to be Held Today at 1:30 p.m. PDT/4:30 p.m. EDT RANCHO CORDOVA, Calif., Aug. 13, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, … Continued
RANCHO CORDOVA, Calif., Aug. 6, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced that the Company will release its financial results for the second quarter ended June 30, 2019 on Tuesday, August 13, 2019 after the close of trading. A conference call … Continued
RANCHO CORDOVA, Calif., July 23, 2019 /PRNewswire/ — ThermoGenesis, a wholly owned subsidiary of Cesca Therapeutics (Nasdaq: KOOL) and a market leader in automated cellular processing, today announced that CBR® (Cord Blood Registry), the country’s largest newborn stem cell storage bank has begun the process to transition to ThermoGenesis’ next-generation AXP® II System for the rapid … Continued
RANCHO CORDOVA, Calif., June 26, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced that on June 25, 2019 the Company received notification from the Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) that it has regained compliance with Nasdaq Listing … Continued
RANCHO CORDOVA, Calif., June 25, 2019 /PRNewswire/ — ThermoGenesis Corp., a wholly owned subsidiary of Cesca Therapeutics (Nasdaq: KOOL), and a market leader in automated cellular processing, today announced that it has entered into a strategic agreement with Cordlife Group Limited (“Cordlife Group”) to provide its proprietary, next-generation AXP® II System, for the rapid processing of cord … Continued
Marks Second Product Approval from Health Canada This Year RANCHO CORDOVA, Calif., June 18, 2019 /PRNewswire/ — ThermoGenesis Corp., a wholly owned subsidiary of Cesca Therapeutics (Nasdaq: KOOL), and a market leader in automated cellular processing, today announced that it has received Health Canada approval of its next-generation AXP®II system for cord blood processing. The AXP® II, together with the … Continued
Company to promote its PXP® cellular processing system RANCHO CORDOVA, Calif., June 5, 2019 /PRNewswire/ — ThermoGenesis Corp., a wholly owned subsidiary of Cesca Therapeutics (Nasdaq: KOOL), and a market leader in automated cellular processing, today announced that it will participate in and exhibit its novel PXP® System, for point-of-care preparation of bone marrow concentrate … Continued
Trading on a Post-Split Basis is Scheduled to Begin on June 5, 2019 RANCHO CORDOVA, Calif., June 4, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced that it has amended its Sixth Amended and Restated Certificate of Incorporation to reflect … Continued
Conference Call to be Held Today at 1:30 p.m. PDT/4:30 p.m. EDT RANCHO CORDOVA, Calif., May 14, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced financial and operating results for the first quarter ended March 31, 2019 and provided a … Continued
RANCHO CORDOVA, Calif., May 7, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cellular processing and autologous cell therapies for regenerative medicine, today announced that the Company will release its financial results for the first quarter ended March 31, 2019 on Tuesday, May 14, 2019 after the close of trading. A conference call and … Continued